Stockreport

ProQR’s QRX-421 for Usher Syndrome receives ODD from FDA and EMA [Seeking Alpha]

ProQR Therapeutics N.V. - Ordinary Shares  (PRQR) 
Last proqr therapeutics n.v. - ordinary shares earnings: 2/26 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: proqr.com
PDF ProQR Therapeutics N.V. (NASDAQ: PRQR ) announces that investigational drug QRX-421 for Usher syndrome has received orphan drug designation (ODD) from the [Read more]